Literature DB >> 28449361

Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.

G Roda1, N Narula2, R Pinotti3, A Skamnelos4, K H Katsanos4, R Ungaro1, J Burisch1, J Torres1, J-F Colombel1.   

Abstract

BACKGROUND: Disease extent in ulcerative colitis is one of the major factors determining prognosis over the long-term. Disease extent is dynamic and a proportion of patients presenting with limited disease progress to more extensive forms of disease over time. AIM: To perform a systematic review and meta-analysis of epidemiological studies reporting on extension of ulcerative colitis to determine frequency of disease extension in patients with limited ulcerative colitis at diagnosis.
METHODS: We performed a systematic literature search to identify studies on disease extension of ulcerative colitis (UC) and predictors of disease progression.
RESULTS: Overall, 41 studies were eligible for systematic review but only 30 for meta-analysis. The overall pooled frequency of UC extension was 22.8% with colonic extension being 17.8% at 5 years and 31% at 10 years. Extension was 17.8% (95% CI 11.2-27.3) from E1 to E3, 27.5% (95% CI 7.6-45.6) from E2 to E3 and 20.8% (95% CI 11.4-26.8) from E1 to E2. Rate of extension was significantly higher in patients younger than 18 years (29.2% (CI 6.4-71.3) compared to older patients (20.2% (CI 13.0-30.1) (P<.0001). Risk of extension was significantly higher in patients from North America (37.8%) than from Europe (19.6%) (P<.0001).
CONCLUSIONS: In this meta-analysis, approximately one quarter of patients with limited UC extend over time with most extension occurring during the first 10 years. Rate of extension depends on age at diagnosis and geographic origin. Predicting those at high risk of disease extension from diagnosis could lead to personalised therapeutic strategies.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28449361      PMCID: PMC6350510          DOI: 10.1111/apt.14063

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

Review 1.  AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Siddharth Singh; Joseph D Feuerstein; David G Binion; William J Tremaine
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

2.  Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Authors:  Neeraj Narula; Farhad Peerani; Joseph Meserve; Gursimran Kochhar; Khadija Chaudrey; Justin Hartke; Prianka Chilukuri; Jenna Koliani-Pace; Adam Winters; Leah Katta; Eugenia Shmidt; Robert Hirten; David Faleck; Malav P Parikh; Diana Whitehead; Brigid S Boland; Siddharth Singh; Sashidhar Varma Sagi; Monika Fischer; Shannon Chang; Morris Barocas; Michelle Luo; Karen Lasch; Matthew Bohm; Dana Lukin; Keith Sultan; Arun Swaminath; David Hudesman; Nitin Gupta; Bo Shen; Sunanda Kane; Edward V Loftus; Corey A Siegel; Bruce E Sands; Jean-Frederic Colombel; William J Sandborn; Parambir S Dulai
Journal:  Am J Gastroenterol       Date:  2018-06-27       Impact factor: 10.864

3.  Molecular Characterization of Limited Ulcerative Colitis Reveals Novel Biology and Predictors of Disease Extension.

Authors:  Carmen Argmann; Minami Tokuyama; Ryan C Ungaro; Ruiqi Huang; Ruixue Hou; Sakteesh Gurunathan; Roman Kosoy; Antonio Di'Narzo; Wenhui Wang; Bojan Losic; Haritz Irizar; Lauren Peters; Aleksandar Stojmirovic; Gabrielle Wei; Phillip H Comella; Mark Curran; Carrie Brodmerkel; Joshua R Friedman; Ke Hao; Eric E Schadt; Jun Zhu; Judy Cho; Noam Harpaz; Marla C Dubinsky; Bruce E Sands; Andrew Kasarskis; Saurabh Mehandru; Jean-Frederic Colombel; Mayte Suárez-Fariñas
Journal:  Gastroenterology       Date:  2021-09-02       Impact factor: 22.682

4.  Factors Predictive of Proximal Disease Extension and Clinical Course of Patients Initially Diagnosed with Ulcerative Proctitis in an IBD Referral Center.

Authors:  Sandro da Costa Ferreira; Lilian Rose Otoboni Aprile; Rogério Serafim Parra; Marley Ribeiro Feitosa; Gleici de Castro da Silva Perdoná; Omar Féres; José Joaquim Ribeiro da Rocha; Luiz Ernesto de Almeida Troncon
Journal:  Turk J Gastroenterol       Date:  2022-04       Impact factor: 1.555

5.  Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort.

Authors:  Johan Burisch; Ryan Ungaro; Ida Vind; Michelle V Prosberg; Flemming Bendtsen; Jean-Frederic Colombel; Marianne K Vester-Andersen
Journal:  J Crohns Colitis       Date:  2017-10-01       Impact factor: 9.071

6.  How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system.

Authors:  Anita Bálint; Klaudia Farkas; Zoltán Szepes; Ferenc Nagy; Mónika Szűcs; László Tiszlavicz; Renáta Bor; Ágnes Milassin; Mariann Rutka; Anna Fábián; Tamás Molnár
Journal:  BMC Gastroenterol       Date:  2018-01-08       Impact factor: 3.067

Review 7.  Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era.

Authors:  Jordan E Axelrad; Shailja C Shah
Journal:  Therap Adv Gastroenterol       Date:  2020-05-06       Impact factor: 4.409

8.  Efficient and Divergent Enantioselective Syntheses of DHPVs and Anti-Inflammatory Effect on IEC-6 Cells.

Authors:  Hyun Su Kim; Sungkyun Chung; Moon-Young Song; Changjin Lim; Hyeyoung Shin; Joonseong Hur; Hyuk Kwon; Young-Ger Suh; Eun-Hee Kim; Dongyun Shin; Seok-Ho Kim
Journal:  Molecules       Date:  2020-05-08       Impact factor: 4.411

Review 9.  Ulcerative Colitis: Current and Emerging Treatment Strategies.

Authors:  Maia Kayal; Shailja Shah
Journal:  J Clin Med       Date:  2019-12-30       Impact factor: 4.241

10.  Assessment of Barriers and Facilitators to the Delivery of Care for Noncommunicable Diseases by Nonphysician Health Workers in Low- and Middle-Income Countries: A Systematic Review and Qualitative Analysis.

Authors:  David J Heller; Anirudh Kumar; Sandeep P Kishore; Carol R Horowitz; Rohina Joshi; Rajesh Vedanthan
Journal:  JAMA Netw Open       Date:  2019-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.